Biotech RadarJobs updated

COMPANY

Upstream Bio

HQ: Waltham, MA source · upstreambio.com ↗ · New England

Clinical Phase 2

Location: Waltham, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Severe Asthma Chronic Rhinosinusitis With Nasal Polyps Chronic Obstructive Pulmonary Disease Asthma Verekitug (UPB-101) Verekitug UPB-101

$293.0MRaised (2 yrs)6Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD source ↗
  2. Trial start Phase 2: A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) source ↗
  3. Raise IPO: $293M (total, as published), announced Oct 15, 2024. Source: company release on GlobeNewswire. source ↗
  4. Trial start Phase 2: A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) source ↗
  5. Trial start Phase 2: A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps source ↗
  6. Trial start Phase 1: Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults source ↗
  7. Trial start Phase 1: Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $293.0M. Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT06164704A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal PolypsPhase 2CompletedDec 18, 2023Jul 7, 2025 (actual)
NCT06981078A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDPhase 2Active, not recruitingJul 2, 20252027-10 (estimated)
NCT06966479A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)Phase 2Active, not recruitingMay 21, 20252027-09 (estimated)
NCT06196879A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)Phase 2CompletedFeb 27, 2024Dec 16, 2025 (actual)
NCT05448651Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in AsthmaticsPhase 1CompletedJul 8, 2022Aug 15, 2023 (actual)
NCT05653479Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian AdultsPhase 1CompletedDec 5, 2022Apr 7, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback